Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257131 | 1.00 | PTGS2 (0.43) | PTGS2PTGS1SLC7A5COMTCA12 | |
| SCHEMBL257159 | 1.00 | PTGS2 (0.43) | PTGS2PTGS1SLC7A5COMTCA12 | |
| Cadaverine Tartrate SCHEMBL1666549 | 0.91 | PTGS2 (0.41) | PTGS2PTGS1SLC7A5COMT | |
| SCHEMBL12367200 | 0.90 | PTGS2 (0.41) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL256549 | 0.90 | CA12 (0.43) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL165364 | 0.90 | CA12 (0.43) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL12669730 | 0.88 | PTGS2 (0.42) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL882938 | 0.88 | PTGS2 (0.42) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL16604228 | 0.85 | PTGS2 (0.40) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL15623815 | 0.82 | SLC7A5 (0.48) | SLC7A5MEN1KMT2AMAPK1HBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170105959-A1 | COMPOSITIONS CONTAINING NITRIC OXIDE AMINO ACID ESTERS AND METHODS FOR IMPROVING SEXUAL PERFORMANCE | SMARTEK INTERNATIONAL, INC. | 2017-04-20 | — | — | US | disclosed |
| US-20150202175-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | FARBER MICHAEL (US) | 2015-07-23 | — | — | US | disclosed |
| US-9085508-B2 | Nitric oxide releasing amino acid ester compound, composition and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085528-B2 | Nitric oxide amino acid ester compound, composition for increasing nitric oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| EP-2342175-B1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NITROGENIX INC (VG) | 2015-05-27 | — | — | EP | disclosed |
| US-20150093338-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | FARBER MICHAEL (US) | 2015-04-02 | — | — | US | disclosed |
| US-8946160-B2 | Nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2015-02-03 | — | — | US | disclosed |
| US-8883844-B2 | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions | NITROGENIX INC. (VG) | 2014-11-11 | — | — | US | disclosed |
| US-20140148438-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | NITROGENIX, INC. (VG) | 2014-05-29 | — | — | US | disclosed |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | FARBER MICHAEL (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012027827-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR SKIN REJUVENATION | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012027827-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR SKIN REJUVENATION | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-03-08 | — | — | WO | disclosed |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | BENOIT & COTE (CA) | 2011-08-11 | — | — | US | disclosed |
| EP-2342175-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | Nitrogenix Inc. (VG) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011057387-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR THE TREATMENT OF CHRONIC PAIN | ORAL DELIVERY TECHNOLOGY LTD . (CA) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057386-A1 | COMPOSITION AND PROPHYLACTIC DEVICE FOR ENHANCING SEXUAL PERFORMANCE OR PLEASURE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2011-05-19 | — | — | WO | disclosed |
| US-20100311780-A1 | Nitric oxide amino acid ester compound, composition for increasing nitirc oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-12-09 | — | — | US | disclosed |
| US-7807716-B2 | Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| WO-2010034118-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076043-A1 | NITRIC OXIDE AMINO ACID ESTER COMPOUND, COMPOSITIONS FOR INCREASING NITRIC OXIDE LEVELS AND METHOD OF USE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202175-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | NOS1, NOS2, NOS3 | PTGS2 166/4885PTGS1 76/4885SLC7A5 52/4885 |
| US-20100076043-A1 | NITRIC OXIDE AMINO ACID ESTER COMPOUND, COMPOSITIONS FOR INCREASING NITRIC OXIDE LEVELS AND METHOD OF USE | NOS1, NOS2, NOS3 | PTGS2 305/4885PTGS1 131/4885SLC7A5 97/4885 |
| US-20140148438-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | NOS2, NOS1, NOS3 | PTGS2 145/4885PTGS1 84/4885SLC7A5 62/4885 |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | PTGS2 68/4885PTGS1 41/4885SLC7A5 89/4885 |
| US-20150093338-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | NOS2, NOS1, NOS3 | PTGS2 145/4885PTGS1 84/4885SLC7A5 62/4885 |
| US-20100311780-A1 | Nitric oxide amino acid ester compound, composition for increasing nitirc oxide levels and method of use | NOS1, NOS2, NOS3 | PTGS2 852/4885PTGS1 334/4885SLC7A5 60/4885 |
| US-20170105959-A1 | COMPOSITIONS CONTAINING NITRIC OXIDE AMINO ACID ESTERS AND METHODS FOR IMPROVING SEXUAL PERFORMANCE | NOS1, NOS2, NOS3 | PTGS2 734/4885PTGS1 358/4885SLC7A5 190/4885 |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | PTGS2 68/4885PTGS1 41/4885SLC7A5 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.